Occurrence of multidrug resistant and ESBL producing E. coli causing urinary tract infections

Urinary tract infection [UTI] forms the largest single group of hospital-acquired infection and account for about 40-50% of the total nosocomial infections. Present study indicates that there is a high prevalence of multidrug resistant E. coli in UTI. Purpose of this study was to find out the occurrence of multidrug resistance among the Escherichia coli, which is the causative agent in more than 80% of urinary tract infection. In this study, 100 isolates were taken from UTI patients and their susceptibility pattern was studied. Minimum inhibitory concentration [MIC] of 11 antibiotics was studied using agar dilution method. The isolates were highly susceptible against imipenem i.e. 91% and were least susceptible to ampicillin and tetracycline. The resistance against ciprofloxacin was also very high i.e. 85%. ESBL production among these E.coli isolates was checked by combination disc method and about 54% isolates were found to be ESBL producers. So our result indicates the fact that the physicians should be aware of this increasing resistance among our local clinical isolates and should change their therapy regime accordingly

Tuberculosis drug resistance patterns At SIUT

Tuberculosis [TB] remains endmic in our population. The growing resistance to drug poses problems in treatment and prevention of this disease and transplanted patients. Immune status of many of the first group and majority of latter is comprised due to illness and drugs respectively. There is thus a predisposition to TB in both these groups and therefore drug sensitivity testing is of extreme importance. At SIUT between Nov 2000 and Dec 2001 a total of routine clinical specimen were cultured for Mycobacteria by using Lowenstein-Jensen [LJ] slants. 77.5% of Mycobacterium tuberculosis were susceptible to all five drugs. Resistance to any drug was 22.5%. Highest resistance was against Isoniazid [13.75%] followed by Streptomycin [11.25%]. Multi drug resistance [MDR] was only1.25%. Drug sensitivity testing has shown the Rifampicin remains resistant free and MDR remains low in our series of patients. However, such testing is necessary in other populations groups since compliance, incomplete treatment and reinfection are major causes of everyday resistance in our population